ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Medicarpin reduces cisplatin resistance and causes apoptosis by inhibiting the AKT/Bcl2 pathway in breast cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Medicarpin Mediates the Protective Effect of Cell Pyroptosis Against Sepsis-Induced Liver Injury by NLRP3/GSDMD/Caspase-1 Axis.Journal of biochemical and molecular toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medicarpin (Med) is a natural flavonoid extract that has demonstrated promising anti-tumor activity in a variety of cancers. The effect of Med on malignant progression and chemotherapy resistance in breast cancer (BC) is currently unclear. Cisplatin-resistant (CisR) MCF-7 cells were constructed. The effects of different doses of Med and Cisplatin (Cis) on the viability of MCF-7 and CisR-MCF-7 cells were examined through Cell Counting Kit-8 (CCK-8) assay. Biological characterization of BC cells was evaluated by EdU staining, Hoechst 33,258 staining, Transwell assay, flow cytometry, and Scratch-wound assay. Comet assay and immunofluorescence to assess cellular DNA damage. Western blot detected DNA damage-related proteins, apoptosis-related protein, cycle-blocking-related protein, and AKT/Bcl2 pathway protein levels. Additionally, a nude mice subcutaneous graft tumor model was constructed, and the impact of Med on tumor growth was explored by pathological staining. The results showed that Med (80 μM) decreased the viability of both MCF-7 and CisR-MCF-7 cells. Either Med or Cis suppressed cell proliferation, hindered migration and invasion, induced apoptosis, and caused cellular DNA damage and cycle arrest. Med blocked the AKT/Bcl2 pathway. All of the above indices were significantly reversed in BC cells after addition of the AKT agonist SC79. However, the AKT inhibitor MK2206 increased the effect of Med, further inhibited the malignant progression of BC cells, and induced cellular DNA damage and cycle arrest. In addition, injection of either Med or Cis caused a decline in Ki67 positivity and a rise in TUNEL positivity in tumor tissues, which in turn suppressed tumor growth. The effect of the combined treatment of the two was higher than single treatment, indicating that Med could improve the therapeutic efficacy of Cis and reduce the drug resistance of CisR-MCF-7 cells. Med inhibits BC malignant biological behavior and reduces Cis resistance by blocking the AKT/Bcl2 pathway.
Indexed as
Identifiers
41134353What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.